Neuraxis Inc (NRXS)
NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions affecting children and adults in the United States. The company’s product lineup includes IB-Stim, a percutaneous electrical nerve field stimulation system intended for patients age 8 and older with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms. It also markets a rectal expulsion device used as a screening tool for evacuation disorders. NeurAxis sells its products primarily to healthcare providers, including hospitals and clinics. Founded in 2011 and based in Carmel, Indiana, the company was previously known as Innovative Health Solutions, Inc. before adopting the NeurAxis name in March 2022. The common stock is listed on the NYSE under the symbol NRXS.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-NRXS
|
$6.87
|
-3.0% Downside
|
Fair
|
$11
|
55.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 17, 2026
|
-10.8x
|
15.2x
|
20.5x
|
84.957 M
|
80.836 M
|
0.4%
|
67.7%
|
4.5
|
—
|
75.2%
|
